早期非小细胞肺癌立体定向放疗的相关研究

doi:10.11904/j.issn.1002-3070.2018.01.010

Abstract

Abstract: At present,approximately 20% of patients with clinically diagnosed early non-small cell lung cancer(NSCLC)are inoperable for their own reasons.Stereotactic radiotherapy(SRT)has the advantages of short treatment time,mild treatment-related injury and high local control rate.Currently,it has been used internationally as a first-line treatment for early incapacity of NSCLC.SRT has also achieved encouraging therapeutic effects in the treatment of early-stage NSCLC,but there are also some problems to be solved urgently.This article aims to summarize the dosimetry,clinical indications and radiotherapy injury of SRT in the treatment of early-stage NSCLC.

Key words: Stereotactic radiotherapy, Early-stage, Non-small cell lung cancer, Peripheral, Central

CLC Number:

R734.2

SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.

References

1 徐向英,曲雅勤,伍刚,等.肿瘤放射治疗学[M].北京:人民卫生出版社,2017:190.
2 Shaverdian N,Wang PC,Steinberg M,et al.The patient′s perspective on stereotactic body radiation therapy vs. surgery for treatment of early stage non-small cell lung cancer[J].Lung Cancer,2015,90(2):230-233.
3 Turzer M,Brustugun OT,Waldeland E,et al.Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity[J].Case Rep Oncol,2011,4(1):25-34.
4 Timmerman RD,Park C,Kavanagh BD,et al.The North American experience with stereotactic body radiation therapy in non-small cell lung cancer[J].J Thorac Oncol,2007,2(7):101-112.
5 Ueki N,Matsuo Y,Shibuya K,et al.Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer[J].J Radiat Res,2012,54(2):337-343.
6 Onishi H,Araki T.Stereotactic body radiation therapy for stage I non-small-cell lung cancer:A historical overview of clinical studies[J].Jpn J Clin Oncol,2013,43(4):345-350.
7 Factor OB,Vu CC,Schneider JG,et al.Stereotactic body radiation therapy for stage I non-small cell lung cancer:A small academic hospital experience[J].Front Oncol,2014,4:287-298.
8 Janssen-Heijnen MLG,Maas HAAM,Houterman S,et al.Comorbidity in older surgical cancer patients:Influence on patient care and outcome[J].Eur J Cancer,2007,43(15):2179-2193.
9 Lagerwaard FJ,Verstegen NE,Haasbeek CJA,et al.Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2012,83(1):348-353.
10 Lischalk JW,Woo SM,Kataria S,et al.Long-term outcomes of stereotactic body radiation therapy with fiducial tracking for in operable stage I non-small cell lung cancer[J].J Radiat Oncol,2016,5(4):379-387.
11 Taremi M,Hope A,Dahele M,et al.Stereotactic body radiotherapy for medically inoperable lung cancer:prospective,single-center study of 108 consecutive patients[J].Int J Radiat Oncol Biol Phys,2012,82(2):967-973.
12 夏廷毅,李宏奇,王颖杰,等.全身γ刀治疗不能手术Ⅰ和Ⅱ期非小细胞肺癌的临床结果[J].中华放射肿瘤学杂志,2007,16(2):91-97.
13 Dunlap NE,Larner JM,Read PW,et al.Size matters:a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy[J].J Thorac Cardiovasc Surg,2010,140(3):583-589.
14 Ricardi U,Frezza G,Filippi AR,et al.Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer:an Italian multicenter observational study[J].Lung Cancer,2014,84(3):248-253.
15 Haasbeek CJ,Lagerwaard FJ,Slotman BJ,et al.Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer[J].J Thorac Oncol,2011,6(12):2036-2043.
16 Fakiris AJ,Mcgarry RC,Yiannoutsos CT,et al.Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma:four-year results of a prospective phase II study[J].Int J Radiat Oncol Biol Phys,2009,75(3):677-682.
17 Davis JN,Medbery C,Sharma S,et al.Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the research patient registry[J].Radiat Oncol,2015,10(1):113-114.
18 Modh A,Rimner A,Williams E,et al.Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy[J].Int J Radiat Oncol Biol Phys,2014,90(5):1168-1176.
19 Wang P,Zhang D,Guo XG,et al.A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly:[J].Medicine,2016,95(52):127-132.
20 Port J L,Parashar B,Osakwe N,et al.A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer[J].Ann Thorac Surg,2014,98(4):1152-1159.
21 Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-637.
22 王建东,左占杰,张洪波,等.电视辅助胸腔镜手术和体部立体定向放疗治疗早期非小细胞肺癌的临床疗效比较[J].中国肺癌杂志,2016,19(3):136-146.
23 Sun B,Brooks ED,Komaki RU,et al.7‐year follow-up after stereotactic ablative radiotherapy for patients with stage I non‐small cell lung cancer:Results of a phase 2 clinical trial[J].Cancer,2017,123(16):3031-3039.
24 王烽,田锋,佟玉筠,等.PET-CT在周围型非小细胞肺癌N分期及淋巴结清扫中的价值[J].中华临床医师杂志(电子版),2013,7(2):609-612.
25 Nambu A,Onishi H,Aoki S,et al.Rib fracture after stereotactic radiotherapy on follow-up thin-section computed tomography in 177 primary lung cancer patients[J].Radiat Oncol,2011,6(1):1-9.
26 Jumeau R,Filion ,Bahig H,et al.A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC[J].Br J Radiol,2017,90(1075):196-197.
27 Nishimura S,Takeda A,Sanuki N,et al.Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors[J].J Thorac Oncol,2014,9(9):1370-1376.
28 Stauder MC,Macdonald OK,Olivier KR,et al.Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions[J].Radiother Oncol,2011,99(2):166-171.
29 Li Q,Swanick CW,Allen PK,et al.Stereotactic ablative radiotherapy(SABR)using 70 Gy in 10 fractions for non-small cell lung cancer:exploration of clinical indications[J].Radiother Oncol,2014,112(2):256-261.
30 Mou B,Merrell KW,Owen DA,et al.Stereotactic body radiation therapy for central lung tumors:outcomes and toxicity:treatment toxicity[J].Int J Radiat Oncol Biol Phys,2014,90(5):80-81.

[1]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[2]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[3]	KONG Fanwei, ZHAO Changjiu. The change of peripheral blood cells after iodine 131 treatment in differentiation thyroid cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 476-479.
[4]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[5]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[6]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[7]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[8]	WANG Jingsheng, LIU Zhengjun, CHENG Nan, LI Dan, GAO Huiguang. Clinical study of peripheral blood T cell subsets in patients with malignant lymphoma by flow cytometry [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 431-435.
[9]	DAI Xin, ZHANG Daxin. Current status of anti-angiogenesis therapy for non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 472-476.
[10]	HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.
[11]	ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.
[12]	REN Fenghai,WANG Dandan,WANG Junfeng,XU Hai,XU Shidong. Clinical comparative study between Uniportal and single port video-assisted thoracoscopic surgery for ⅠA stage non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 327-331.
[13]	YE Leiguang, YAN An, LIU Baogang. Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 97-102.
[14]	CHEN Minghui, CHEN Xijie, WANG Yan. Research progress of CD44v6 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 172-175.
[15]	CHENG Long, ZHOU Jianguo, ZHOU Hang. Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 28-35.

Stereotactic radiotherapy for early stage of non - small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments